In metabolic outcome trials, significant effects on weight reduction were shown with semaglutide (GLP-1RA) [48–51] and tirzepatide (dual GIP/GLP-1 RA)[52–57] in people with or without T2D. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.